Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery

Syrimi, Eleni, Fennell, Eanna, Richter, Alex, Vrljicak, Pavle, Stark, Richard, Ott, Sascha, Murray, Paul G., Al-Abadi, Eslam, Chikermane, Ashish, Dawson, Pamela, Hackett, Scott, Jyothish, Deepthi, Kanthimathinathan, Hari Krishnan, Monaghan, Sean, Nagakumar, Prasad, Scholefield, Barnaby R., Welch, Steven, Khan, Naeem, Faustini, Sian, Davies, Kate ORCID: https://orcid.org/0000-0002-9807-1231, Zelek, Wioleta M., Kearns, Pamela and Taylor, Graham S. 2021. The immune landscape of SARS-CoV-2-associated multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. iScience 24 (11) , 103215. 10.1016/j.isci.2021.103215

[thumbnail of The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery.pdf]
Preview
PDF - Published Version
Available under License Creative Commons Attribution.

Download (8MB) | Preview

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a life-threatening disease occurring several weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Deep immune profiling showed acute MIS-C patients had highly activated neutrophils, classical monocytes and memory CD8+ T-cells, with increased frequencies of B-cell plasmablasts and double-negative B-cells. Post treatment samples from the same patients, taken during symptom resolution, identified recovery-associated immune features including increased monocyte CD163 levels, emergence of a new population of immature neutrophils and, in some patients, transiently increased plasma arginase. Plasma profiling identified multiple features shared by MIS-C, Kawasaki Disease and COVID-19 and that therapeutic inhibition of IL-6 may be preferable to IL-1 or TNF-α. We identified several potential mechanisms of action for IVIG, the most commonly used drug to treat MIS-C. Finally, we showed systemic complement activation with high plasma C5b-9 levels is common in MIS-C suggesting complement inhibitors could be used to treat the disease.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Additional Information: Creative Commons Attribution 4.0 International (CC BY 4.0)
Publisher: Cell Press
ISSN: 2589-0042
Date of First Compliant Deposit: 18 November 2021
Date of Acceptance: 26 September 2021
Last Modified: 20 May 2023 21:44
URI: https://orca.cardiff.ac.uk/id/eprint/145592

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics